Leveraging AAV gene therapy for safe durable expression of cytokine immunotherapies

all companies
milestones

Founded 2020

Partnered 2021

Team

Nicole Paulk

Board
LEAD INVESTOR

Vasudev Bailey

category
Oncology
Immunology

Combining the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single, powerful new treatment modality to fight cancer

No items found.